Prostate Cancer Registry Presents First Treatment Outcome Data

Prostate Cancer Registry Presents First Treatment Outcome Data
Metastatic castration-resistant prostate cancer (mCRPC) patients who have never received chemotherapy benefit more from treatment than post-chemotherapy patients, according to the first reported outcome data from the The Prostate Cancer Registry, Europe’s first and largest prospective study of men with mCRPC. The results, presented by Janssen-Cilag International at the European Society for Medical Oncology 2016 Congress, which took place Oct. 7-11 in Copenhagen,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Brian Haselum says:

    Currently I am receiving treatment for early metastasis of PC receiving 6 doses Docetaxel and Goselerin hormone therapy. Since Aug 15 my PSA has dropped from 1.4 to 0.30

Leave a Comment

Your email address will not be published. Required fields are marked *